AUTHOR=Costa-Rocha Ismael Artur da , Campi-Azevedo Ana Carolina , Peruhype-Magalhães Vanessa , Coelho-dos-Reis Jordana Grazziela , Fradico Jordana Rodrigues Barbosa , Souza-Lopes Thalles , Reis Laise Rodrigues , Freire Larissa Chaves , Costa-Pereira Christiane , Mambrini Juliana Vaz de Melo , Maia Maria de Lourdes de Sousa , Lima Sheila Maria Barbosa de , Noronha Tatiana Guimarães de , Xavier Janaina Reis , Camacho Luiz Antonio Bastos , Albuquerque Elizabeth Maciel de , Farias Roberto Henrique Guedes , Castro Thalita da Matta de , Homma Akira , Romano Alessandro Pecego Martins , Domingues Carla Magda , Martins Reinaldo de Menezes , Teixeira-Carvalho Andréa , Martins-Filho Olindo Assis TITLE=Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine JOURNAL=Frontiers in Immunology VOLUME=10 YEAR=2019 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.01211 DOI=10.3389/fimmu.2019.01211 ISSN=1664-3224 ABSTRACT=

The present study aims to determine whether 17DD-YF-specific humoral and cellular immunological memory is maintained 8-years after primary vaccination with subdoses (10,447IU;3,013IU;587IU;158IU;31IU). For this purpose, this follow-up study was carried out in a subset of volunteers (n = 98) originally enrolled in the dose-response study in 2009 and 46 non-vaccinated controls. Our results demonstrated that vaccinees, who had seroconverted following primary vaccination and had not been revaccinated, present similar neutralizing antibodies levels and YF-specific cellular memory, particularly CMCD4 and EMCD8 as compared to the reference full dose (27,476IU). Although, PRNT seropositivity rates were similar across subgroups (94, 82, 83, 94, 80, and 91%, correspondingly), only doses above 587IU elicited similar iterative proportion of seropositivity rates, calculated as a progressive decrease on seropositivity rates along time (89, 80, 80, and 91%, respectively) as compared to 158IU and 31IU (68 and 46%, respectively). Noteworthy were the strong positive correlations (“EMCD4,EMCD8” and “TNFCD8,IFNCD8”) observed in most subdoses, except for 31IU. Major similarities underscored the preserved antibody titers and the outstanding levels of EMCD8, relevant correlates of protection for YF-specific immunity. These findings provide evidences to support the regular use of dose sparing strategy for YF vaccine in adults.